Opendata, web and dolomites

CL-IO SIGNED

Commercial feasibility of non-pathogenic Clostridium-Mediated Cancer Immunotherapy: leveraging the presence of tumour hypoxia & necrosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CL-IO project word cloud

Explore the words cloud of the CL-IO project. It provides you a very rough idea of what is the project "CL-IO" about.

tumour    gain    combating    l19    immunocytokine    tumors    limited    benefit    start    lambin    malignancies    hypoximmuno    modality    escape    251022032    producing    immunotherapies    poc    cancer    technological    model    immune    release    strategy    commercialisation    tumours    delivering    urgency    trimodal    exact    colonise    feasibility    precision    off    routes    stereotactic    business    regions    mechanisms    io    prof    checkpoint    accelerator    https    patients    respect    cl    bacteria    solid    prepare    factories    hypoxic    selectively    com    push    position    radiotherapy    market    mortality    strategies    proof    necrosis    experts    modified    break    inhibitor    14    overcome    lung    first    powerful    watch    inclusion    optimal    erc    hypoxia    despite    minority    immunotherapeutic    il2    spin    immunotherapeutics    proven    worldwide    dictated    incidence    agents    limitation    strategic    cellular    weapons    necrotic    act    therapy    cancers    immunotherapy    clostridium    ip    vimeo    rates    genetically    therapeutic    positioning    team    commercial    antibody    site    innovative    sought    suppression   

Project "CL-IO" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT MAASTRICHT 

Organization address
address: Minderbroedersberg 4-6
city: MAASTRICHT
postcode: 6200 MD
website: http://www.maastrichtuniversity.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 150˙802 €
 EC max contribution 150˙000 € (99%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) coordinator 150˙000.00

Map

 Project objective

Immunotherapeutic strategies are powerful weapons in combating malignancies. However, only a minority of patients benefit from this therapeutic modality, as tumours develop mechanisms of immune escape and suppression and uptake of (antibody-based) agents in tumors is limited. The urgency of investigating novel strategic approaches is dictated by the high incidence and mortality rates of cancer worldwide. Lung cancer, in particular, is the leading cancer with respect to incidence and mortality (14% of new cancers). In the ERC Advanced “HYPOXIMMUNO”, Prof. Lambin and his team have investigated the trimodal therapy involving high precision Stereotactic Radiotherapy, hypoxia/necrosis targeting and tumour specific immunotherapy (immunocytokine L19-IL2 to “push the accelerator” with a checkpoint inhibitor to “release the break”). Despite promising results, the delivery of immunotherapeutics to the tumour site has proven to be challenging. Prof. Lambin and his team have sought to overcome this limitation with the inclusion of genetically-modified Clostridium bacteria as optimal delivery system capable of effectively delivering immunotherapeutics within the tumour. These Clostridium-bacteria selectively colonise the hypoxic/necrotic regions present in solid tumours and act as cellular factories capable of continuously producing tumour-specific immunotherapies within the tumour (watch https://vimeo.com/251022032 ). In this ERC PoC project, a team of technological and commercial experts will investigate the commercial feasibility of this innovative approach. We will prepare the first steps towards the start-up of a spin-off, by defining the exact business strategy, model and positioning for commercial success. We will develop the business strategy based on the technological aspects, the market needs and trends, and the IP-position. During CL-IO, we will gain technical and commercial proof-of-concept, providing the necessary information for potential commercialisation routes.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CL-IO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CL-IO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More